Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-27
2007-03-27
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
11060914
ABSTRACT:
A method for reducing intraocular pressure and increasing outflow facility from an eye of a subject having glaucoma includes the step of providing in the trabecular meshwork of the eye an amount of caldesmon effective to reduce intraocular pressure and increase outflow facility.
REFERENCES:
patent: 5798380 (1998-08-01), Kaufman et al.
patent: 6110912 (2000-08-01), Kaufman et al.
patent: 6555107 (2003-04-01), Poeschla et al.
patent: 6586425 (2003-07-01), Kaufman et al.
patent: 2002/0045585 (2002-04-01), Kaufman et al.
Andrawiss, M., et al., “Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma,” J. Gene. Med., 3:228-239 (2001).
Borras, T., et al., “Ocular adenovirus gene transfer varies in efficiency and inflammatory response,” Invest Ophthalmol. Vis. Sci., 37:1282-1293 (1996).
Borras, T., et al., “Gene transfer to the human trabecular meshwork by anterior segment perfusion,” Invest Ophthalmol Vis Sci., 39:1503-1507 (1998).
Borras, T., et al., “Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow. Relevance for potential gene therapy of glaucoma” Gene her 6:515-524 (1999).
Borras, T., et al., “Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo,” J. Gene. Med., 3:437-449 (2001).
Borras, T., et al., “Gene Therapy for Glaucoma: Treating a Multifaceted, Chronic Disease,” Invest. Ophthalmol. Vis. Sci., 43:2513 (2002).
Budenz, D., et al., “In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells,” Invest. Ophthalmol. Vis. Sci., 36:2211-2215 (1995).
Hauswirth, W. & Beaufrere, L., “Ocular Gene Therapy: Quo Vadis?,” Invest. Ophthalmol. Vis. Sci., 41:2821-2826 (2000).
Helfman, D., et al., “Caldesmon inhibits non-muscle cell contractility and interferes with the formation of focal adhesions,” Mol. Biol. Cell, 10:3097-3112 (1999).
Kee, C., et al., “Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo,” Invest. Ophthalmol. Vis. Sci., 42:2856-2860 (2001).
Loewen, N., et al., “Preservation of Aqueous Outflow Facility after Second-Generation FIV Vector-Mediated Expression of Marker Genes in Anterior Segments of Human Eyes,” Invest. Ophthalmol. Vis. Sci. 43:3686-3690 (2002).
Loewen, N., et al., “Long-Term, Targeted Genetic Modification of the Aqueous Humor Outflow Tract Coupled with Noninvasive Imaging of Gene Expression In Vivo,” Invest. Ophthalmol. Vis. Sci. 45:3091-3098 (2004).
Loewen N., et al., “Long-term retinal transgene expression with FIV versus adenoviral vectors,” Mol Vis., 10:272-280 (2004).
Nakamura, Y., et al., “Signaling mechanism of TGF-beta1-induced collagen contraction mediated by bovine trabecular meshwork cells,” Invest. Ophthalmol. Vis. Sci. 43:3465-3472 (2002).
Gabelt, B.T., et al., “Outflow Facility Enhancement By Caldesmon Gene Therapy In Organ-Cultured Human and Monkey Eyes,” Invest Ophthalmol Vis Sci 45: E-Abstract 1032 (2004).
Haxhinasto, Kari, et al., “Gene Delivery of 1-caldesmon Protects Cytoskeletal Cell Membran Integrity Against Adenovirus Infection Independently of Myosin ATPase and Actin Assembly” Am J Phsiol 287:C1125-C1138 (2004).
Liu, Xuyang, et al., “Herpes Simplex Virus Mediated Gene Transfer to Primate Ocular Tissues,” Exp. Eye Res. 69, 385-395 (1999).
Santas, Amy J., et al., “Effect of Heparin II Domain of Fibronectin on Aqueous Outflow in Cultured Anterior Segments of Human Eyes,” Investigative Ophthalmology & Visula Science vol. 44, No. 11 (Nov. 2003).
Geroski & Edelhauser, “Drug delivery for posterior segment eye disease,” Invest. Ophthlamol. Vis. Sci. 41:961-964 (2000).
Fialho & da Silva-Cunha, “New vehicle based on a microemulsion for topical ocular administration of dexamethasone,” Clin. Experiment. Ophthalmol. 32:626-632 (2004).
Friedberg et al., “Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps,” Ophthalmology 98:725-732 (1991).
Isowaki et al., “Drug delivery to the eye with a transdermal therapeutic system,” Biol. Pharm. Bull. 26:69-72 (2003).
Pijls et al., “Studies on a new device for drug delivery to the eye,” Eur. J. Pharm. Biopharm. 9:283-288 (2005).
Bershadsky Alexander
Borras Teresa
Geiger Benjamin
Kaufman Paul L.
Rooke Agnes B.
Wisconsin Alumni Research Foundation
Yeda Research and Development Co. Ltd.
LandOfFree
Method for treating glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767425